西藏藥業(600211.SH):2022年度擬使用不超8億元閒置資金進行現金管理
格隆匯3月11日丨西藏藥業(600211.SH)公佈,為了提高公司自有閒置資金的利用率,公司將按照《投資理財管理制度》等相關規定,結合公司的實際情況,利用暫時閒置的自有資金進行現金管理,購買安全性高、有保本約定的產品,以獲得較好的收益。2022年度,在不影響公司業務正常發展和確保公司資金需求的前提下,擬用於進行現金管理佔用的資金餘額不超過人民幣8億元(含8億元),授權經營管理層負責實施(有效期至2022年年度股東大會之日)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.